Artificial Intelligence driven Marketing Communications
Global “Age-Related Macular Degeneration (AMD) Therapeutics market” 2019-2023 report offers a complete evaluation of this market, highlighting the growth boosters, obstructions, future prospects, and the changing competitive aspect of this market. It also obtains the most prominent market trends and the current and previous performance of this market in order to determine its status in the near future.
Request a sample copy of the report –https://www.absolutereports.com/enquiry/request-sample/14439887
Age-Related Macular Degeneration (AMD) Therapeutics Market analysts forecast the global Age-Related Macular Degeneration (AMD) Therapeutics market to grow at a CAGR of over 8% during the period 2019-2023.
Age-related macular degeneration (AMD) is a bilateral ocular disease that affects the central area of the retina known as the macula. Our age-related macular degeneration considers sales from both wet AMD, dry AMD. Our analysis also considers the sales of AMD in Asia, Europe, North America and ROW. In 2018, the wet AMD segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing use of VEGF inhibitors, which are used for the treatment of wet AMD will play a significant role in the wet AMD segment to maintain its market position. Also, our global age-related macular degeneration market report also looks at factors such as high prevalence of AMD, strong pipeline and expected approvals, and rising geriatric populations. However, lack of approved therapies for dry AMD, introduction of biosimilars, side effects of available therapeutics may hamper the growth of the age-related macular degeneration industry over the forecast period.
Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Manufacturers includes:
and many more.
Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Regions includes: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America, Middle East and Africa.
Market Driver: high prevalence of AMD Market Trend: development of gene therapy for AMD Market Challenge: side effects of available therapeutics. High prevalence of AMD The prevalence of AMD is extremely high, owing to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period. Development of gene therapy for AMD There is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.
Inquire or share your questions if any before the purchasing this report – https://www.absolutereports.com/enquiry/pre-order-enquiry/14439887
Key questions answered in this report
Purchase this Report (Price 2500 USD for a Single-User License)
Table of Contents
TOC of Keyword Market ReportPART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Wet AMD – Market size and forecast 2018-2023 Dry AMD – Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America – Market size and forecast 2018-2023 Europe – Market size and forecast 2018-2023 Asia – Market size and forecast 2018-2023 ROW – Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Strategic alliances Development of gene therapy for AMD Growing awareness about AMD PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS
Name: Ajay More
Phone: US +1424 253 0807/ UK +44 203 239 8187
Mail id: [email protected]
Our Other Report:
Sports Car Market with several features of the industry like the market size, market status, market trends and forecast, the report also offers brief information of the competitors and the specific growth opportunities with key market drivers.
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit Age-Related Macular Degeneration (AMD) Therapeutics Market Share, Size 2019 Movements by Global Trend Analysis, Growth Status, Revenue Expectation to 2023 | Says Absolutereports.com